Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy

P and T

Volumn 38, Issue 11, 2013, Pages 696-701

  Awad, Nadia I ^a,b   Cocchio, Craig ^c  

^a RUTGERS UNIVERSITY   (United States)

^b Somerset Medical Center   (United States)

^c ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Activated PCC; Anticoagulation; FEIBA; Hemorrhage; Reversal

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; APIXABAN; BOEHRINGER INGELHEIM; DABIGATRAN; DABIGATRAN ETEXILATE; FONDAPARINUX; FRESH FROZEN PLASMA; GLAXOSMITHKLINE; JANSSEN; KANOKAD; PFIZER; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THROMBIN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT ASSOCIATED COAGULOPATHY; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING DISORDER; CONTINUOUS INFUSION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG COST; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; PARTIAL THROMBOPLASTIN TIME;

EID: 84887847980     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs. intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: A prospective randomized controlled study. Arch Intern Med 2003;163(20):2469-2473.
2. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial. Ann Intern Med 2002;137(4):251-254
3. Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999;159(22):2721-2724.
4. Ageno W, Gallus AS, Wittkowsky A, et al. Oral Anticoagulant Therapy-Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2)(Suppl):e44S-e88S
5. Popovsky MA. Transfusion-related acute lung injury: Incidence, pathogenesis, and the role of multicomponent apheresis in its prevention. Transfus Med Hemother 2008;35(2):76-79.
6. Hellstern P. Production and composition of prothrombin complex concentrates: Correlation between composition and therapeutic efficiency. Thrombosis Res 1999;95(4 Suppl 1):S7-S12.
7. FEIBA NF, prescribing information. Westlake Village, Calif.: Baxter Healthcare Corp.; 2011.
8. Wojcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2009;2:217-225.
9. Desmurs-Clavel H, Huchon C, Chatard B, et al. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC, and PCC. Thrombosis Res 2009;123:796-798.
10. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: Mode of action. Haemophilia 2004;10(Suppl 2):3-9.
11. van Ryn J, Ruehl D, Priepke H, et al. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica 2008;93(Suppl 1):148.
12. Perzborn E, Gruber A, Tinel H, et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013;110 (online).
13. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal of agents on anticoagulant activity of dabigatran and rivaroxaban. J Thrombosis Haemost 2012;108:217-224.
14. Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006,4:967-970.
15. van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. Thromb Res 2006;118:313-320.
16. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): Efficacy and safety in 42 patients. Br J Haematol 2002;116:619-624.
17. Pabinger-Fasching I: Warfarin-reversal: Results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate. Thromb Res 2008;122(Suppl 2):S19-S22.
18. Bagot CN, Cregg R, Patel RK, et al. Perioperative myocardial infarction in a patient receiving low-dose prothrombin complex concentrates. Thromb Haemost 2007;98:1141-1142.
19. Warren O, Simon B. Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate. Ann Emerg Med 2009;53:758-761.
20. Kohler M, Hellstern P, Lechler E, et al. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 1998;80:399-402.
21. Pabinger I, Tiede A, Kalina U, et al. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: A prospective clinical trial of emergency anticoagulation reversal. Ann Hematol 2010;89:309-316.
22. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA): Addressing safety issues. Haemophilia 2008;14:39-43.
23. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-298.
24. Yank V, Tuohy V, Logan AC, et al. Effectiveness of off-label use of recombinant factor VIIa. Ann Intern Med 2011;154:529-540.
25. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010;363:1791-1800.
26. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999;95:S13-S17.
27. Gallistl S, Cvirn G, Leschnik B, Muntean W. Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA. Blood Coagul Fibrinol 2002;13:653-655.
28. Red Book. Greenwood Village, Colo.: Thomson Reuters (Healthcare) Inc.; June 14, 2013.
29. Sakata T, Kario K, Matsuo T, et al. Suppression of plasma-activated factor VII levels by warfarin therapy. Arterioscler Thromb Vasc Biol 1995;15:241-246